Interesting trends are emerging for the big pharmaceutical companies as they try to brandish new drug launches, dash into untapped — previously rated insignificant — markets, release their scientific data gathered over the years for wider use and application and assertively trim their overweight staff strengths in all departments starting at the labs and ending at the doctor’s clinic.

Effient, the clot buster developed by Daiichi Sankyo and Eli Lilly, does not seem to have done much to erode sales of its bigger rival Plavix, which is co-marketed by Sanofi-Aventis and Bristol Myers-Squibb.

In its calls with analysts, Daiichi Sankyo executives admitted that sales were moderate but indicated that the product will be more appreciated in the coming years as knowledge gets spread out on the exact way it demonstrated therapeutic advantages over clopidogrel.

Daiichi Sankyo may be right but considering that the blood thinner is also associated with serious bleeding issues as pointed out by the US Food and Drug Administration may not make it an easier choice for the doctors.

Also, it is generally seen that if a product does not get appreciated in the first few months of its launch, it may not succeed in generating large sales or qualify as being called a blockbuster.

That may be a premature assumption as Daiichi Sankyo has not undertaken a global rollout plan especially through its Ranbaxy arm in key markets.

Comments

Search RSS

All rights reserved."